The first week of 2018 has offered a sting of good news and along with the positive sentiments of the market has given a fantastic lift to the portfolio. I hope this will continue throughout the year! In an earlier post, I promised to tell about my mistakes and miscalculation around the Dignitana issue. This is a story much better told after some profitable days. Losing money is today’s theme – luckily, it was mine … not yours! Continue reading
It is Christmas at last and despite stormy weather and lack of snow, I appreciate the days of with my family. I hope you find time for that as well.
During December, four of the companies in my portfolio asked for more money. The companies are CybAero, Cantargia, Recyctec and Dignitana. In this post, I will follow up on the issues and say a few words on the perspectives. Continue reading
Last year almost all companies in the portfolio asked for more money and made issues. On this front, this year has been quiet – until now. The last two months, though, CybAero, Dignitana, Cantargia and Recyctec have announced private and preferential right issues – and there is a warrant series due as well, which I got as part of A1M Pharma’s issue in June 2016. In other words, I could easily switch Christmas presents for shares – but I am not sure that my sons will be happy. Continue reading
In April BrainCool announced a preferential rights issue. The subscription period began on May 15th and ends at May 29th. The issue price is 5 SEK, which is slightly under the current share price of 5.30 SEK (Friday May 19th). Presumably, the issue will be oversubscribed and company will raise the intended 58.5 MSEK. For my part, I will subscribe all I can using my warrants. Continue reading
The short week before Easter gave us news about A1 Pharma’s issue and CybAero’s troubles with the Swedish Inspectorate of Strategic Products (ISP) – both affecting share prices negatively. Both shares fell heavily and the share prices are in both cases close to 1 SEK…A1M’s price is 0.92 SEK and CybAero’s 1.29. Reduced to penny shares, in other words. Continue reading
On Wednesday (April 5th) the trading of BrainCool shares were stopped in the late afternoon with no explanation. There were a number of theories on the internet ranging from the CEO has left with the remaining money to stories that the BrainCool System had received clearance from the Australian Department of Health. What made the latter theory credible was the links to the Australian homepage. This story received confirmation on Thursday morning before opening of Aktietorget and trading reopened at 9. Two and a half hour later, another press release came from BrainCool … a preferential rights issue in May. Continue reading
This week has been one of the most volatile weeks when I look at the shares in my portfolio. Top 4 of largest changes this week are: A1M down 40 %, CybAero up 15 %, Cantargia up 9 %, and Dignitana up 8 %. For some of this there a understandable reasons – for others there are not.
A1M – volatile weeks ‘winner’
The shares plunged this week! Down 40 %. For some reason the share price have kept its height even though there was a coming issue. This week changed this.
The prospectus also came out this week. In short: The subscription period began at March 24th and ends April 7th. For 2.25 SEK you get a unit. Each unit contains three shares and one free warrant. After the issue the company will merger 20 shares into one new and apply for listing on Nasdaq First North in Stockholm. Continue reading
When A1M Pharma announced an issue February 7th the share market acted as always and started a steep slide towards the issue price of 0.75 SEK. The day before the announcement, the share closed at 1.97. Three days later, it had dropped to half the price – 0.98 SEK. So far, everything was normal. Usually the share price then would move a little closer to the issue price ending perhaps with a premium of 5-25 % for taking the risk. What we see in A1M is something quite different. Continue reading
Well, Recyctec announced the outcome of the issue in February this week. The preferential rights issue had a 100 percent guarantee, which came into use since current shareholders subscribed only 44 % and other investors accounted for 26 %. The guarantors covered the rest – 30 %.
The outcome came as a surprise to me since the prospects of the company are good. There are no known competitors, the company is riding on the huge Green Wave, Recyctec have distribution agreements with a number of distributors, and this issue ought to bring the company to break even in 2017. Then why does only 44 % of the current shareholders have the faith in the company and are willing to subscribe? Continue reading
A1M Pharma announced a preferential rights issue on the 7th of February. This is the third issue in 2017 in my portfolio. So far, Cantargia, Recyctec and now A1M has asked for additional funding. If this issue pace continues throughout the year I am not sure that I have sufficient savings to hang in! Continue reading